Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Helicobacter pylori Infections - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Helicobacter pylori Infections - Pipeline Review, H1 2016', provides an overview of the Helicobacter pylori Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections - The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects - The report assesses Helicobacter pylori Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Helicobacter pylori Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Helicobacter pylori Infections Overview 7 Therapeutics Development 8 Pipeline Products for Helicobacter pylori Infections - Overview 8 Pipeline Products for Helicobacter pylori Infections - Comparative Analysis 9 Helicobacter pylori Infections - Therapeutics under Development by Companies 10 Helicobacter pylori Infections - Therapeutics under Investigation by Universities/Institutes 11 Helicobacter pylori Infections - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Helicobacter pylori Infections - Products under Development by Companies 15 Helicobacter pylori Infections - Products under Investigation by Universities/Institutes 16 Helicobacter pylori Infections - Companies Involved in Therapeutics Development 17 Daewoong Pharmaceutical Co., Ltd. 17 Debiopharm International S.A. 18 EpiVax, Inc. 19 Frost Biologic, Inc. 20 ImevaX GmbH 21 ImmunoBiology Limited 22 RedHill Biopharma Ltd. 23 Sequella, Inc. 24 Sigmoid Pharma Limited 25 Helicobacter pylori Infections - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 33 Drug Profiles 35 (amoxicillin sodium + omeprazole sodium + rifabutin) - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Debio-1453 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 DWJ-1325 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 FROST-900 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Helicobacter pylori vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Helicobacter pylori vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Helicobacter pylori vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Helicobacter pylori vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 HPi-1 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 IMX-101 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules for Helicobacter Pylori Infections - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 SQ-109 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Helicobacter pylori Infections - Recent Pipeline Updates 54 Helicobacter pylori Infections - Dormant Projects 58 Helicobacter pylori Infections - Product Development Milestones 59 Featured News & Press Releases 59 Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study's Positive Results 59 Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection 60 Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection 61 Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection 62 Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study 62 Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results 63 May 18, 2015: RedHill Biopharma's Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market 66 May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study 67 Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection 67 Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment 68 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for Helicobacter pylori Infections, H1 2016 8 Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Helicobacter pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 17 Helicobacter pylori Infections - Pipeline by Debiopharm International S.A., H1 2016 18 Helicobacter pylori Infections - Pipeline by EpiVax, Inc., H1 2016 19 Helicobacter pylori Infections - Pipeline by Frost Biologic, Inc., H1 2016 20 Helicobacter pylori Infections - Pipeline by ImevaX GmbH, H1 2016 21 Helicobacter pylori Infections - Pipeline by ImmunoBiology Limited, H1 2016 22 Helicobacter pylori Infections - Pipeline by RedHill Biopharma Ltd., H1 2016 23 Helicobacter pylori Infections - Pipeline by Sequella, Inc., H1 2016 24 Helicobacter pylori Infections - Pipeline by Sigmoid Pharma Limited, H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Assessment by Combination Products, H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Mechanism of Action, H1 2016 31 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Helicobacter pylori Infections Therapeutics - Recent Pipeline Updates, H1 2016 54 Helicobacter pylori Infections - Dormant Projects, H1 2016 58
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.